Research Project 2
Project title: Developing an Orally Bioavailable SERD for Treatment of Metastatic/Advanced Breast Cancer
PI: Guangdi Wang, Ph.D.
Overall goal/objective:
The goal of this proposal is to determine the in vivo efficacy of ZB716 to inhibit ER+ breast cancer using patient derived xenograft models. In vitro studies using tamoxifen resistant MCF-7 cells have demonstrated that the ZB716 are effective in inhibiting the growth and proliferation of the estrogen dependent, but tamoxifen resistant breast cancer cells (MCF-7/TamR). In order for the drug candidates to move towards eventual clinical trials, the next critical step is to show in vivo efficacy in the most clinically relevant animal models. Moreover, we need to show that orally administered ZB716 can achieve equivalent or better tumor suppression effect compared to the standard treatment of fulvestrant s.c. injection. Mice will be used because of their short gestation time, well-defined genetics, and well-developed procedures for xenograft models.
Research discipline: Basic Biomedical